Julie R. Brahmer, MD, discusses tumor vaccines for patients with lung cancer.
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses tumor vaccines for patients with lung cancer.
Brahmer says several lung cancer tumor vaccines are currently in phase II or phase III trials and physicians are eager to hear if they will improve patient survival.
During the 2013 ASCO Annual Meeting, it was announced that the BLP-MUC1 vaccine did not seem to improve survival in patients who received chemotherapy and radiation sequentially. However, patients who received a combination of chemotherapy and radiation seemed to do better when also receiving the vaccine compared to placebo, Brahmer says.
A trial looking at the MAGE-3 vaccine in an adjuvant setting is one of the largest studies done in lung cancer. Brahmer hopes that the MAGE-3 vaccine will be the next tumor vaccine to be approved for lung cancer.
Clinical Pearls
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More